Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Uveitis, Posterior Clinical Trial

Official title:

An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03145025
• Other study ID #: 853
• Status: Completed
• Start date: July 14, 2017
• Est. completion date: March 22, 2019

Study information

• Verified date: June 2019
• Source: Bausch & Lomb Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant

Description:

This is a prospective, multicenter, open-label, single arm, observational evaluation of the corneal ECD change from baseline for subjects having the Retisert FA drug delivery system (0.59 mg) surgically implanted in the ocular vitreous chamber of at least 1 previously unimplanted eye for at least 1 year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: March 22, 2019
• Est. primary completion date: September 10, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Are scheduled for surgical placement of a Retisert fluocinolone acetonide (FA) intravitreal implant in a previously unimplanted eye.

2. Are able and willing to comply with all treatment and follow up/study procedures.

3. Able and willing to provide informed consent or, for subjects 12-18 years of age, have the ability to understand and provide assent (when applicable) and whose parent/legally authorized representative has the ability to understand and provide written informed consent on the Institutional Review Board (IRB) approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.

4. For female subjects:

Note: Should a subject conceive during the study, the pregnancy should be reported as soon as possible to the study Medical Monitor and Promedica International within 24 hours. The pregnancy will be followed up to term. The subject will continue in the studyregardless if pregnancy is reported on an AE/SAE form. If an Investigator becomes aware of a post study pregnancy 30 days after the study exit visit while Fluocinolone Acetonide Implant remains in the subject's study eye, then it should be reported as a post-marketing report

Exclusion Criteria:

1. Has previously, concurrently or anticipated enrollment in Bausch & Lomb study 440, titled, "An Observational Bilateral Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant for at Least One Year."

2. Has severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study, based on the judgment of the Investigator.

3. Has participated in an ophthalmic drug or device research study within 30 days prior to Screening (Visit 1, Day -30 to -1) in this study

4. Is monocular (unable to detect hand motion at 6 feet in 1 eye).

5. Has a known corneal dystrophy or corneal transplant.

6. Has a history of ocular surgery in the eye scheduled for implant surgery, including laser procedures, within the 30 days prior to Screening (Visit 1, Day -30 to -1).

7. Had any type of intraocular drug delivery implant (eg, Retisert, Ozurdex [dexamethasone intravitreal implant]) in the study eye.

Related Conditions & MeSH terms

• Uveitis
• Uveitis, Posterior

Intervention

Device:
• Retisert
Intravitreal Implant

Drug:
• Fluocinolone Acetonide Intravitreal Implant
Intravitreal Implant

Locations

Country	Name	City	State
United States	Valeant Site 001	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary safety endpoint is change from baseline in endothelial cell density (ECD) in the study eye one year following implantation.		1 year